NEW YORK – The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich said Thursday that they are collaborating to build a single-cell atlas to better understand cancer plasticity in response to therapies.

纽约——Wellcome Sanger研究所、Parse生物科学公司和慕尼黑亥姆霍兹计算健康中心周四表示，他们正在合作构建一个单细胞图谱，以更好地理解癌症在治疗下的可塑性。

In a statement, the partners said they're ultimately aiming to build a single-cell dataset of hundreds of millions of cells based on analyzing 3D organoid cultures. These data could inform computational models of drug effects on tumors and cancer mechanisms of plasticity and adaptability in response to treatments..

合作伙伴在一份声明中说，他们最终的目标是基于对 3D 类器官培养物的分析，构建一个包含数亿个细胞的单细胞数据集。这些数据可以为药物对肿瘤的影响和癌症对治疗反应的可塑性和适应性机制的计算模型提供信息。

Under the terms of the deal, Parse will generate single-cell RNA sequencing data through its GigaLab services.

根据协议条款，Parse 将通过其 GigaLab 服务生成单细胞 RNA 测序数据。

Financial and other terms of the deal were not disclosed.

交易的财务条款及其他条款均未披露。

'Our vision of a virtual cell perturbation model is becoming increasingly feasible with recent advances in artificial intelligence — but to scale effectively, we need large, high-quality single-cell perturbation datasets,' said Fabian Theis, director of the Computational Health Center at Helmholtz Munich and an associate researcher at the Sanger Institute.

“我们对虚拟细胞扰动模型的设想随着人工智能的最新进展变得越来越可行——但为了有效扩展，我们需要大型、高质量的单细胞扰动数据集，”赫尔姆霍兹慕尼黑计算健康中心主任、桑格研究所副研究员法比安·蒂斯表示。

He and Sanger's Mathew Garnett will serve as principal investigators. 'This collaboration enables that scale, and I'm excited to move toward AI-driven experimental design in drug discovery.'.

他和桑格的马修·加内特将担任主要研究者。 “这次合作能够实现这一规模，我期待在药物发现方面朝着人工智能驱动的实验设计迈进。”

The deal follows a

这笔交易紧随其后的是一个

collaboration

协作

late last year among Parse, Ultima Genomics, and Tahoe Therapeutics (formerly Vevo Therapeutics) to create a 100 million-cell dataset for use in AI-based drug discovery.

去年年底，Parse、Ultima Genomics 和 Tahoe Therapeutics（前身为 Vevo Therapeutics）合作创建了一个用于AI药物发现的1亿细胞数据集。